Events

  • 2017-03-26
    On March 8th, 2017 Julphar Bangladesh launched Doxair 200 (Doxophylline 200 mg), a novophylline ensuring easy breathing and indicated for the treatment of asthma, Chronic Obstructive Pulmonary Disease (COPD) and bronchospasm.   Doxophylline is a…
  • 2017-03-26
    Julphar has made a record-breaking achievement in the Saudi market, with its product MEBO being ranked No. 1 product in the KSA IMS Health of February 2017.   MEBO recorded a 24% growth over last year in terms of value among all pharmaceuticals…
  • 2017-03-26
    Julphar is in the process of launching electronic procurement software with POOL4TOOL to enhance its purchase processing.   During a meeting that took place on March 23rd, 2017 in the Julphar head office of Ras Al Khaimah, CEO Dr Ayman Sahli –…
  • 2017-03-23
    On March 22nd, 2017 Julphar and Emirates Foundation have signed a partnership agreement. With this agreement, Julphar will work closely with the Foundation and give its support in achieving the Foundation’s vision of inspiring, empowering and guiding…
  • 2017-03-22
    As part of its commitment to support research activities and ensure the sustainability of patients’ safety, Julphar Bangladesh invited over 40 doctors to attend a Continuing Medical Education (CME) program on infections control in Intensive Care…